This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates
by Kinjel Shah
Lilly (LLY) signs deal with AbCellera to co-develop antibody therapies to treat COVID-19. AbbVie (ABBV) supports studies evaluating Kaletra for treating COVID-19.
Weekly Biotech Update After WHO Declares Coronavirus a Pandemic
by Zacks Equity Research
Several pharma/companies are working to develop a treatment for novel coronavirus as WHO declares Covid-19 a pandemic.
Coronavirus Drug Development Efforts Pick Up Amid Sell-Off
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.
Roche's (RHHBY) Coronavirus Test Achieves EUA From the FDA
by Zacks Equity Research
Roche's (RHHBY) cobas SARS-CoV-2 Test for the qualitative detection of SARS-CoV-2, the virus that causes the COVID-19 disease, gets EUA from the FDA.
Bristol Myers' Opdivo+Yervoy Combo Gets FDA Nod for HCC
by Zacks Equity Research
Bristol Myers (BMY) gets FDA approval for the Opdivo and Yervoy combination for the treatment of HCC.
Top Research Reports for Alibaba, Roche & Intel
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Alibaba Group (BABA), Roche Holding (RHHBY) and Intel (INTC).
Bristol-Myers Empliciti Combo Fails in First-Line Myeloma Study
by Zacks Equity Research
Bristol-Myers' (BMY) Empliciti, Revlimid and dexamethasone combination regimen fails to improve progression free survival in first-line multiple myeloma patients.
Is Amgen (AMGN) Truly One of the Best Biotech Stocks to Own?
by Zacks Equity Research
Amgen (AMGN) boasts a strong biosimilars portfolio, which can drive long-term growth. Amgen is also progressing with its pipeline while regularly pursuing business development deals.
Puma Biotech's (PBYI) Nerlynx Aids Growth Despite Competition
by Zacks Equity Research
Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. High dependence on Nerlynx for growth remains a woe.
Can-Fite (CANF) to Explore RA Drug for Coronavirus Treatment
by Zacks Equity Research
Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.
Infinity (INFI) Q4 Loss Wider Than Expected, IPI-549 in Focus
by Zacks Equity Research
Infinity (INFI) posts a wider-than-expected loss for the fourth quarter of 2019.
Alnylam's Givlaari Gets Approval in Europe for Rare Disease
by Zacks Equity Research
Alnylam's (ALNY) second RNAi-based therapeutics, Givlaari receives approval in Europe for treating acute hepatic porphyria, becoming the first and only approved therapy for the indication.
Roche's Esbriet Gets FDA Breakthrough Tag for New Indication
by Zacks Equity Research
Roche (RHHBY) gets Breakthrough Therapy status from the FDA for Esbriet in adults with unclassifiable interstitial lung disease.
AbbVie's Venclexta Combo Fails in Late-Stage Leukemia Study
by Zacks Equity Research
AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with chemotherapy fails to achieve statistically significant improvement in overall survival in treatment-naive AML patients.
Oncolytics (ONCY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During Q4 investors' call, Oncolytics (ONCY) is likely to provide an update on the studies of pelareorep, which is being developed for treating solid tumors and hematological malignancies.
Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit
by Kinjel Shah
FDA accepts Glaxo (GSK) and Novartis' (NVS) sBLA. FDA gives approval to Lilly's (LLY) Trulicity for cardiovascular indication.
Immunomedics (IMMU) Reports Wider-Than-Expected Q4 Loss
by Zacks Equity Research
Immunomedics (IMMU) posts wider-than-expected Q4 loss. Its BLA seeking accelerated approval for sacituzumab govitecan in metastatic triple-negative breast cancer (mTNBC) is accepted for filing by FDA.
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates
by Zacks Equity Research
Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.
Exelixis (EXEL) Beats on Earnings, Misses on Sales in Q4
by Zacks Equity Research
Exelixis' (EXEL) Q4 results are a mixed bag, as earnings beat, while sales marginally miss estimates.
Halozyme (HALO) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Halozyme (HALO) reports wider-than-expected loss and misses revenue estimates in fourth-quarter 2019. Shares down.
Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are looking forward to Cabometyx's performance and pipeline updates, when Exelixis (EXEL) reports Q4 results.
Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
by Kinjel Shah
AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.
Puma (PBYI) Stock Down Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
Puma Biotech (PBYI) incurs narrower loss in Q4 and tops sales estimates. Sales of Nerlynx decline year over year. Stock drops 10%.
Roche's Tecentriq sBLA for Lung Cancer Gets Priority Review
by Kinjel Shah
Roche (RHHBY) gets FDA's priority review status for a sBLA for Tecentriq monotherapy in first-line treatment of certain people with advanced non-small cell lung cancer.
ImmunoGen (IMGN) Q4 Earnings & Sales Beat, Shares Rally
by Zacks Equity Research
ImmunoGen (IMGN) reports fourth-quarter results with earnings and revenues beating estimates.